Overview
Iktos is a leading French AI company specializing in deep learning applications for medicinal chemistry and drug design. As of 2026, Iktos has solidified its position as a top-tier provider of generative modeling solutions for de novo design (Makya) and AI-powered retrosynthesis (Spaya). Their technical architecture leverages advanced Deep Generative Models, including Reinforcement Learning and Variational Autoencoders, to navigate vast chemical spaces while optimizing for multiple parameters simultaneously (MPO). Unlike traditional docking-based virtual screening, Iktos focuses on generating synthetically accessible molecules that meet specific ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiles. The 2026 market position of Iktos is defined by its 'Iktos Robotics' integration—a closed-loop platform that combines generative software with automated chemical synthesis hardware. This synergy addresses the primary bottleneck in drug discovery: the cycle time between molecular design and physical testing. Their platform is utilized by global pharmaceutical giants and mid-sized biotech firms to reduce the 'Design-Make-Test-Analyze' cycle from months to weeks, utilizing proprietary algorithms that ensure high synthetic feasibility and structural diversity.